145 related articles for article (PubMed ID: 8627535)
1. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
Compton DR; Aceto MD; Lowe J; Martin BR
J Pharmacol Exp Ther; 1996 May; 277(2):586-94. PubMed ID: 8627535
[TBL] [Abstract][Full Text] [Related]
2. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
3. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.
Wiley JL; Jefferson RG; Grier MC; Mahadevan A; Razdan RK; Martin BR
J Pharmacol Exp Ther; 2001 Mar; 296(3):1013-22. PubMed ID: 11181936
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.
Freedland CS; Whitlow CT; Miller MD; Porrino LJ
Synapse; 2002 Aug; 45(2):134-42. PubMed ID: 12112406
[TBL] [Abstract][Full Text] [Related]
5. CB1 cannabinoid receptor-mediated modulation of food intake in mice.
Wiley JL; Burston JJ; Leggett DC; Alekseeva OO; Razdan RK; Mahadevan A; Martin BR
Br J Pharmacol; 2005 Jun; 145(3):293-300. PubMed ID: 15778743
[TBL] [Abstract][Full Text] [Related]
6. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
8. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
9. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Beardsley PM; Martin BR
Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
[TBL] [Abstract][Full Text] [Related]
10. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
11. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism.
Lichtman AH; Martin BR
Psychopharmacology (Berl); 1996 Jul; 126(2):125-31. PubMed ID: 8856831
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity.
Wiley JL; Jefferson RG; Griffin G; Liddle J; Yu S; Huffman JW; Martin BR
Pharmacology; 2002 Oct; 66(2):89-99. PubMed ID: 12207116
[TBL] [Abstract][Full Text] [Related]
14. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists.
Costa B; Colleoni M
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1103-8. PubMed ID: 11189200
[TBL] [Abstract][Full Text] [Related]
15. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
[TBL] [Abstract][Full Text] [Related]
16. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity.
Compton DR; Martin BR
J Pharmacol Exp Ther; 1997 Dec; 283(3):1138-43. PubMed ID: 9399986
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments.
Rubino T; Viganò D; Zagato E; Sala M; Parolaro D
Synapse; 2000 Jan; 35(1):8-14. PubMed ID: 10579803
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.
Meschler JP; Howlett AC; Madras BK
Psychopharmacology (Berl); 2001 Jun; 156(1):79-85. PubMed ID: 11465637
[TBL] [Abstract][Full Text] [Related]
19. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice.
Collins DR; Pertwee RG; Davies SN
Br J Pharmacol; 1995 Jul; 115(6):869-70. PubMed ID: 7582512
[TBL] [Abstract][Full Text] [Related]
20. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith PB; Welch SP; Martin BR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
